LUC00129I2 - - Google Patents

Info

Publication number: LUC00129I2
Authority: LU; Luxembourg

Application number

LU00129C

Original Assignee

Genmab As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-26

Filing date

2019-10-02

Publication date

2024-05-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00129(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2019-10-02 Application filed by Genmab As filed Critical Genmab As

2024-05-22 Publication of LUC00129I2 publication Critical patent/LUC00129I2/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

LU00129C 2006-09-26 2019-10-02 LUC00129I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US84732906P	2006-09-26	2006-09-26
DKPA200601232		2006-09-26

Publications (1)

Publication Number	Publication Date
LUC00129I2 true LUC00129I2 (fr)	2024-05-22

Family

ID=39156080

Family Applications (3)

Application Number	Title	Priority Date
LU00128C LUC00128I2 (fr)	2006-09-26	2019-10-02
LU00129C LUC00129I2 (fr)	2006-09-26	2019-10-02
LU00130C LUC00130I2 (fr)	2006-09-26	2019-10-02

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LU00128C LUC00128I2 (fr)	2006-09-26	2019-10-02

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LU00130C LUC00130I2 (fr)	2006-09-26	2019-10-02

Country Status (24)

Country	Link
US (4)	US9040050B2 (fr)
EP (3)	EP3753576A1 (fr)
JP (7)	JP5476122B2 (fr)
AU (2)	AU2007302448C1 (fr)
CA (1)	CA2664740C (fr)
CY (7)	CY1121813T1 (fr)
DK (1)	DK2081595T3 (fr)
EA (1)	EA034877B1 (fr)
ES (1)	ES2732278T3 (fr)
FI (1)	FIC20250018I1 (fr)
FR (7)	FR19C1056I1 (fr)
HR (1)	HRP20191115T1 (fr)
HU (7)	HUE044136T2 (fr)
IL (2)	IL197727A (fr)
LT (8)	LT2081595T (fr)
LU (3)	LUC00128I2 (fr)
ME (1)	ME03503B (fr)
NZ (1)	NZ576122A (fr)
PL (1)	PL2081595T3 (fr)
PT (1)	PT2081595T (fr)
RS (1)	RS59005B1 (fr)
SI (1)	SI2081595T1 (fr)
TR (1)	TR201910145T4 (fr)
WO (1)	WO2008037257A2 (fr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1866338B1 (fr) *	2005-03-23	2016-09-21	Genmab A/S	Anticorps diriges contre cd38 pour le traitement du myelome multiple
ES2732278T3 (es) *	2006-09-26	2019-11-21	Genmab As	Anti-CD38 más corticosteroides más un agente quimioterapéutico no corticosteroideo para el tratamiento de tumores
EP2191841A1 (fr) *	2008-11-28	2010-06-02	Sanofi-Aventis	Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et vincristine
EP2191842A1 (fr) *	2008-11-28	2010-06-02	Sanofi-Aventis	Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cytarabine
EP2191840A1 (fr) *	2008-11-28	2010-06-02	Sanofi-Aventis	Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et melphalan
KR20120094472A (ko) *	2009-10-21	2012-08-24	이뮤노젠 아이엔씨	신규한 복용 요법 및 치료 방법
RS59769B1 (sr)	2010-06-09	2020-02-28	Genmab As	Antitela protiv humanog cd38
CN103118706B (zh) *	2010-09-27	2016-05-18	莫佛塞斯公司	抗cd38抗体与来那度胺或硼替佐米用于治疗多发性骨髓瘤和nhl
UA112170C2 (uk) *	2010-12-10	2016-08-10	Санофі	Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) *	2010-12-30	2017-06-16	Takeda Pharmaceuticals Co	الأجسام المضادة لـ cd38
SI2707030T1 (sl)	2011-05-09	2020-10-30	Mayo Foundation For Medical Education And Research	Zdravljenje raka
JP6184965B2 (ja)	2011-10-28	2017-08-23	テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド	ポリペプチド構築物およびその使用
JP6426093B2 (ja)	2012-09-25	2018-11-28	モルフォシス・アーゲー	組み合わせ及びその使用
AU2013327638B2 (en)	2012-10-01	2018-06-14	Mayo Foundation For Medical Education And Research	Cancer treatments
UA118255C2 (uk) *	2012-12-07	2018-12-26	Санофі	Композиція, яка містить антитіло до cd38 і леналідомід
US10342869B2 (en)	2012-12-07	2019-07-09	The Regents Of The University Of California	Compositions comprising anti-CD38 antibodies and lenalidomide
PT2968555T (pt) *	2013-03-13	2020-07-14	Univ California	Composições compreendendo anticorpos anti-cd38 e carfilzomib
KR102094022B1 (ko)	2013-04-29	2020-03-30	테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디	항-cd38 항체 및 감쇠 인터페론 알파-2ｂ와의 융합체
US11117975B2 (en)	2013-04-29	2021-09-14	Teva Pharmaceuticals Australia Pty Ltd	Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
CA2927099A1 (fr) *	2013-10-31	2015-05-07	Sanofi	Anticorps anti-cd38 specifiques pour le traitement de cancers humains
US9603927B2 (en)	2014-02-28	2017-03-28	Janssen Biotech, Inc.	Combination therapies with anti-CD38 antibodies
US9732154B2 (en)	2014-02-28	2017-08-15	Janssen Biotech, Inc.	Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
UA119352C2 (uk) *	2014-05-01	2019-06-10	Тева Фармасьютикалз Острейліа Пті Лтд	Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
MX380597B (es)	2014-06-13	2025-03-12	Mayo Found Medical Education & Res	Composición con complejos de nanopartículas/anticuerpos de paclitaxel unidos a albúmina para usarse al tratar linfoma.
EP3834889A1 (fr) *	2014-06-16	2021-06-16	Mayo Foundation for Medical Education and Research	Traitement de myélomes
WO2016022589A2 (fr) *	2014-08-08	2016-02-11	The Regents Of The University Of California	Méthodes de traitement du myélome multiple
MX386886B (es) *	2014-09-09	2025-03-12	Janssen Biotech Inc	Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
US9446148B2 (en)	2014-10-06	2016-09-20	Mayo Foundation For Medical Education And Research	Carrier-antibody compositions and methods of making and using the same
UA125637C2 (uk)	2014-10-29	2022-05-11	Тева Фармасьютікалз Острейліа Пті Лтд	ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b
EA037084B9 (ru)	2014-12-04	2021-08-05	Янссен Байотек, Инк.	Антитела к cd38 для лечения острого миелолейкоза
PT3294769T (pt)	2015-05-13	2021-04-13	Morphosys Ag	Tratamento para mieloma múltiplo (mm)
WO2016187546A1 (fr) *	2015-05-20	2016-11-24	Janssen Biotech, Inc.	Anticorps anti-cd38 pour le traitement de l'amyloïdose à chaînes légères et d'autres tumeurs malignes hématologiques positives à cd38
JP6871919B2 (ja)	2015-06-16	2021-05-19	ナノファギックスエルエルシー	薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
AU2016282674B2 (en)	2015-06-22	2022-01-13	Janssen Biotech, Inc.	Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US20170044265A1 (en)	2015-06-24	2017-02-16	Janssen Biotech, Inc.	Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
SMT202400127T1 (it) *	2015-06-24	2024-05-14	Janssen Biotech Inc	Modulazione immunitaria e trattamento di tumori solidi con anticorpi che si legano specificamente a cd38
TW201707725A (zh)	2015-08-18	2017-03-01	美國馬友醫藥教育研究基金會	載體－抗體組合物及其製造及使用方法
TW201713360A (en)	2015-10-06	2017-04-16	Mayo Foundation	Methods of treating cancer using compositions of antibodies and carrier proteins
US10781261B2 (en)	2015-11-03	2020-09-22	Janssen Biotech, Inc.	Subcutaneous formulations of anti-CD38 antibodies and their uses
CA3004152C (fr)	2015-11-03	2024-04-16	Janssen Biotech, Inc.	Formulations sous-cutanee d'anticorps anti-cd38 et leurs utilisations
WO2017120501A1 (fr)	2016-01-07	2017-07-13	Mayo Foundation For Medical Education And Research	Procédés de traitement du cancer par interféron
US11351254B2 (en)	2016-02-12	2022-06-07	Mayo Foundation For Medical Education And Research	Hematologic cancer treatments
CA3018341A1 (fr)	2016-03-21	2017-09-28	Mayo Foundation For Medical Education And Research	Procedes de reduction de la toxicite d'un medicament chimiotherapeutique
US11878061B2 (en)	2016-03-21	2024-01-23	Mayo Foundation For Medical Education And Research	Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en)	2016-04-06	2020-04-14	Mayo Foundation For Medical Education And Research	Carrier-binding agent compositions and methods of making and using the same
JP2019527678A (ja)	2016-06-28	2019-10-03	ユーエムセー・ユトレヒト・ホールディング・ベー・フェー	ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
CN117330747A (zh)	2016-07-15	2024-01-02	武田药品工业株式会社	用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料
CN109843336A (zh)	2016-09-01	2019-06-04	梅约医学教育与研究基金会	用于靶向t细胞癌症的方法和组合物
AU2017318668A1 (en)	2016-09-01	2019-03-21	Mayo Foundation For Medical Education And Research	Carrier-PD-L1 binding agent compositions for treating cancers
RU2021128415A (ru)	2016-09-06	2021-11-08	Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч	Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения
US11590098B2 (en)	2016-09-06	2023-02-28	Mayo Foundation For Medical Education And Research	Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
KR102486057B1 (ko)	2016-09-06	2023-01-10	메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치	Ｐｄ－ｌ１ 발현 암의 치료 방법
WO2018098348A1 (fr)	2016-11-23	2018-05-31	Acetylon Pharmaceuticals, Inc.	Combinaisons pharmaceutiques comprenant un inhibiteur d'histone désacétylase et un inhibiteur de cd38 et leurs méthodes d'utilisation
BR112019011450A2 (pt)	2016-12-09	2019-10-15	Onkimmune Limited	células naturais killer modificadas e uso das mesmas
AU2018313028B2 (en) *	2017-08-10	2023-05-25	Grifols Diagnostic Solutions Inc.	Compositions, methods and/or kits comprising a recombinant human CD38-extracellular domain
WO2019035938A1 (fr)	2017-08-16	2019-02-21	Elstar Therapeutics, Inc.	Molécules multispécifiques se liant à bcma et leurs utilisations
CA3079242A1 (fr)	2017-10-31	2019-05-09	Janssen Biotech, Inc.	Methodes de traitement du myelome multiple a haut risque
JP2021510737A (ja)	2018-01-12	2021-04-30	武田薬品工業株式会社	抗ｃｄ３８抗体の皮下投与
JP6648171B2 (ja) *	2018-02-02	2020-02-14	テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド	抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
CA3100118A1 (fr)	2018-05-16	2019-11-21	Janssen Biotech, Inc.	Anticorps bispecifiques bcma/cd3 et gprdc5d/cd3 aux fins d'utilisation dans le traitement du cancer
MA53123A (fr)	2018-07-13	2021-05-19	Genmab As	Thérapie à médiation par trogocytose utilisant des anticorps cd38
SG11202012993SA (en)	2018-07-13	2021-02-25	Genmab As	Variants of cd38 antibody and uses thereof
EP3860342A4 (fr) *	2018-10-03	2022-08-03	Prescient Pharma LLC	Compositions et méthodes pour isoler des cellules circulantes
AU2020242228B2 (en)	2019-03-15	2025-12-11	Morphosys Ag	Anti-CD38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
WO2020250033A1 (fr)	2019-06-10	2020-12-17	Takeda Pharmaceutical Company Limited	Polythérapies utilisant des anticorps cd-38
GB201916150D0 (en)	2019-11-06	2019-12-18	Univ Of Ireland Galway	Treatment of multiple myeloma
CN112876563B (zh)	2019-11-29	2022-08-16	康诺亚生物医药科技（成都）有限公司	药物组合物及其制备方法和应用
JP6853392B2 (ja) *	2020-01-15	2021-03-31	テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド	抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
BR112022013553A2 (pt)	2020-01-16	2022-09-06	Genmab As	Composição farmacêutica, anticorpo, e, método para tratar uma doença
MX2022010549A (es)	2020-02-26	2022-11-16	Biograph 55 Inc	Moleculas de union compuestas que se dirigen a celulas b inmunodepresoras.
WO2021226584A1 (fr) *	2020-05-08	2021-11-11	University Of Southern California	Conjugués anticorps-médicament spécifiques au site par adp-ribosyl cyclases
EP4208202A4 (fr) *	2020-09-01	2024-10-02	The Regents Of The University Of California	Compositions d'anticorps anti immunoglobuline e et procédés d'utilisation
EP4277930A1 (fr)	2021-01-14	2023-11-22	MorphoSys AG	Anticorps anti-cd38 et leurs utilisations
TW202302642A (zh)	2021-03-01	2023-01-16	德商莫菲西斯公司	用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
TW202321303A (zh)	2021-07-19	2023-06-01	德商莫菲西斯公司	抗pla2r自體抗體媒介膜性腎病變之治療
WO2024094660A1 (fr)	2022-10-31	2024-05-10	Genmab A/S	Anticorps cd38 et leurs utilisations
US12173081B2 (en)	2023-03-21	2024-12-24	Biograph 55, Inc.	CD19/CD38 multispecific antibodies

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4474893A (en)	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
JPS6147500A (ja)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
JPS61134325A (ja)	1984-12-04	1986-06-21	Teijin Ltd	ハイブリツド抗体遺伝子の発現方法
US5618920A (en) *	1985-11-01	1997-04-08	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
EP0247091B1 (fr)	1985-11-01	1993-09-29	Xoma Corporation	Assemblage modulaire de genes d'anticorps, anticorps ainsi prepares et utilisation
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US4954617A (en)	1986-07-07	1990-09-04	Trustees Of Dartmouth College	Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5750172A (en)	1987-06-23	1998-05-12	Pharming B.V.	Transgenic non human mammal milk
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
WO1989008114A1 (fr)	1988-02-25	1989-09-08	The General Hospital Corporation	Procede de clonage par immunoselection rapide
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5633076A (en)	1989-12-01	1997-05-27	Pharming Bv	Method of producing a transgenic bovine or transgenic bovine embryo
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
CA2109602C (fr)	1990-07-10	2002-10-01	Gregory P. Winter	Methodes de production de membres de paires de liaison specifiques
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
IE912466A1 (en)	1990-07-13	1992-01-15	Gen Hospital Corp	Rapid immunoselection cloning method
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en)	1990-08-29	2001-10-09	Genpharm International	Transgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69133476T2 (de)	1990-08-29	2006-01-05	GenPharm International, Inc., Palo Alto	Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en)	1990-08-29	1999-02-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5194594A (en)	1990-09-07	1993-03-16	Techniclone, Inc.	Modified antibodies
CA2405246A1 (fr)	1990-12-03	1992-06-11	Genentech, Inc.	Methode d'enrichissement de proteines variantes aux proprietes liantes a lterees
ATE363532T1 (de)	1991-03-01	2007-06-15	Dyax Corp	Verfahren zur herstellung bindender miniproteine
CA2108147C (fr)	1991-04-10	2009-01-06	Angray Kang	Banques de recepteurs heterodimeriques construites a l'aide de phagemides
WO1994004679A1 (fr)	1991-06-14	1994-03-03	Genentech, Inc.	Procede pour fabriquer des anticorps humanises
AU2235992A (en)	1991-06-14	1993-01-12	Genpharm International, Inc.	Transgenic immunodeficient non-human animals
CA2113113A1 (fr)	1991-07-08	1993-01-21	Simon W. Kantor	Copolymere sequence a cristaux liquides thermotropiques
DE4122599C2 (de)	1991-07-08	1993-11-11	Deutsches Krebsforsch	Phagemid zum Screenen von Antikörpern
EP0605522B1 (fr)	1991-09-23	1999-06-23	Medical Research Council	Méthodes de production d'anticorps humanisés
JPH05244982A (ja)	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
GB9223377D0 (en)	1992-11-04	1992-12-23	Medarex Inc	Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
WO1994017184A1 (fr)	1993-01-29	1994-08-04	Schering Corporation	Modulation de la reponse physiologique de lymphocytes par les molecules cd38 ou leurs anti-corps
WO1994019935A1 (fr)	1993-03-09	1994-09-15	Genzyme Corporation	Isolement de constituants d'interet du lait
CA2161351C (fr)	1993-04-26	2010-12-21	Nils Lonberg	Animaux transgeniques, pouvant produire des anticorps heterologues
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
GB9424449D0 (en)	1994-12-02	1995-01-18	Wellcome Found	Antibodies
WO1998016245A1 (fr)	1996-10-15	1998-04-23	Shionogi & Co., Ltd.	Procede de determination d'un auto-anticorps
DE69719529T2 (de)	1996-10-17	2003-12-11	Immunomedics, Inc.	Nichtantigenes toxinkonjugat und fusionsprotein eines internalisierendes rezeptorsystems
WO2000006194A2 (fr)	1997-02-05	2000-02-10	Biotransplant, Inc.	Depletion de cellules responsables du rejet d'une greffe induit par des anticorps
AU745823B2 (en)	1997-05-02	2002-04-11	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Immunotoxins, comprising an onc protein, directed against malignant cells
US6171586B1 (en) *	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
US6719977B1 (en)	1998-02-12	2004-04-13	The General Hospital Corporation	Methods to potentiate cancer therapies
WO1999050392A1 (fr)	1998-03-31	1999-10-07	Geron Corporation	Techniques et compositions permettant de faire apparaitre une reponse immunitaire a un antigene de telomerase
EP1085882A2 (fr) *	1998-06-05	2001-03-28	Mayo Foundation For Medical Education And Research	Traitement du myelome multiple au moyen d'anticorps du cd38 obtenus par genie genetique
WO2000009160A1 (fr) *	1998-08-11	2000-02-24	Idec Pharmaceuticals Corporation	Therapies d'association contre les lymphomes malins a cellules b par l'administration d'anticorps anti-cd20
US7223397B1 (en)	1999-01-07	2007-05-29	Research Development Foundation	Potentiation of anti-CD38-Immunotoxin cytotoxicity
US20050037969A1 (en) *	1999-05-14	2005-02-17	Arbor Vita Corporation	Molecular interactions in hematopoietic cells
EP1210372B1 (fr)	1999-07-29	2008-01-23	Medarex, Inc.	Anticorps monoclonaux humains diriges contre her2/neu
EP1212422B1 (fr)	1999-08-24	2007-02-21	Medarex, Inc.	Anticorps contre l'antigene ctla-4 humain et utilisation
EP1174440A1 (fr)	2000-07-19	2002-01-23	U-BISys B.V.	Un épitope exprimé sélectivement sur la molécule humaine CD38 et détecté par un fragment d'un anticorps humain de forme scFv dérivé d'une librairie "phage display"
US20070042436A1 (en)	2000-10-17	2007-02-22	Lund Frances E	CD38 modulated chemotaxis
JP4139214B2 (ja)	2000-10-17	2008-08-27	トリュデュインスティチュート，インク．	Ｃｄ３８により調節される走化性
AU2002235141A1 (en)	2000-11-27	2002-06-03	Geron Corporation	Glycosyltransferase vectors for treating cancer
IL155977A0 (en)	2000-11-30	2003-12-23	Medarex Inc	Transgenic transchromosomal rodents for making human antibodies
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
IL159225A0 (en)	2001-06-13	2004-06-01	Genmab As	Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US20040166490A1 (en)	2002-12-17	2004-08-26	Morris David W.	Novel therapeutic targets in cancer
US20040019915A1 (en) *	2002-04-01	2004-01-29	Challita-Eid Pia M.	Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer
EP1393720A1 (fr)	2002-08-27	2004-03-03	Universiteit Utrecht	Vesicules encapsulant des corticosteroides pour le traitement du cancer
CA2502552C (fr) *	2002-10-17	2019-02-12	Genmab A/S	Anticorps monoclonaux humains anti-cd20
WO2004045512A2 (fr)	2002-11-15	2004-06-03	Genmab A/S	Anticorps monoclonaux humains contre cd25
ES2373947T3 (es)	2002-12-16	2012-02-10	Genmab A/S	Anticuerpos monoclonales humanos contra interleucina 8 (il-8).
JP4733635B2 (ja) *	2003-07-31	2011-07-27	イミューノメディクス、インコーポレイテッド	抗ｃｄ１９抗体
EP1689435A4 (fr)	2003-10-22	2007-10-03	Univ Rochester	Antiserum anti-thymocyte et son utilisation pour declencher l'apoptose des cellules b
ATE474599T1 (de) *	2003-11-04	2010-08-15	Novartis Vaccines & Diagnostic	Verwendung von antagonisten-anti-cd40- monoklonalen antikörpern zur behandlung von multiplem myelom
EP1684758A4 (fr) *	2003-11-06	2009-02-18	Celgene Corp	Methodes et compositions faisant appel a du thalidomide pour le traitement et pour la gestion de cancers et d'autres maladies
ES2541489T3 (es) *	2004-02-06	2015-07-21	Morphosys Ag	Anticuerpos humanos anti-CD38 y usos para ellos
AU2005235811B2 (en) *	2004-02-06	2011-11-03	Morphosys Ag	Anti-CD38 human antibodies and uses therefor
US20050266008A1 (en) *	2004-03-29	2005-12-01	Medarex, Inc.	Human anti-IRTA-5 antibodies
KR20070004081A (ko) *	2004-04-21	2007-01-05	다이니폰 인사츠 가부시키가이샤	칼라필터 및 그를 갖춘 액정표시장치
US20060019303A1 (en) *	2004-07-23	2006-01-26	Boehringer Ingelheim Pharmaceuticals, Inc.	Method to identify and analyze genes having modified expression in stimulated T cells
EP1866338B1 (fr) *	2005-03-23	2016-09-21	Genmab A/S	Anticorps diriges contre cd38 pour le traitement du myelome multiple
TW200745162A (en)	2005-05-24	2007-12-16	Morphosys Ag	Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
ES2732278T3 (es) *	2006-09-26	2019-11-21	Genmab As	Anti-CD38 más corticosteroides más un agente quimioterapéutico no corticosteroideo para el tratamiento de tumores
US20090076249A1 (en) *	2007-09-19	2009-03-19	Michel De Weers	Antibodies against CD38 for treatment of multiple myeloma

2007
- 2007-09-26 ES ES07817816T patent/ES2732278T3/es active Active
- 2007-09-26 AU AU2007302448A patent/AU2007302448C1/en active Active
- 2007-09-26 HU HUE07817816A patent/HUE044136T2/hu unknown
- 2007-09-26 EP EP20174826.6A patent/EP3753576A1/fr not_active Withdrawn
- 2007-09-26 PL PL07817816T patent/PL2081595T3/pl unknown
- 2007-09-26 LT LTEP07817816.7T patent/LT2081595T/lt unknown
- 2007-09-26 EP EP07817816.7A patent/EP2081595B1/fr active Active
- 2007-09-26 HR HRP20191115TT patent/HRP20191115T1/hr unknown
- 2007-09-26 EP EP19168122.0A patent/EP3569245A1/fr active Pending
- 2007-09-26 NZ NZ576122A patent/NZ576122A/xx unknown
- 2007-09-26 CA CA2664740A patent/CA2664740C/fr active Active
- 2007-09-26 SI SI200732115T patent/SI2081595T1/sl unknown
- 2007-09-26 PT PT07817816T patent/PT2081595T/pt unknown
- 2007-09-26 WO PCT/DK2007/000418 patent/WO2008037257A2/fr not_active Ceased
- 2007-09-26 EA EA200970317A patent/EA034877B1/ru active Protection Beyond IP Right Term
- 2007-09-26 DK DK07817816.7T patent/DK2081595T3/da active
- 2007-09-26 TR TR2019/10145T patent/TR201910145T4/tr unknown
- 2007-09-26 US US12/442,808 patent/US9040050B2/en active Active
- 2007-09-26 RS RS20190880A patent/RS59005B1/sr unknown
- 2007-09-26 ME MEP-2019-194A patent/ME03503B/fr unknown
- 2007-09-26 JP JP2009529534A patent/JP5476122B2/ja active Active
2009
- 2009-03-19 IL IL197727A patent/IL197727A/en active IP Right Grant
2013
- 2013-04-09 AU AU2013203186A patent/AU2013203186C1/en active Active
2014
- 2014-02-07 JP JP2014021875A patent/JP2014141492A/ja active Pending
- 2014-12-10 US US14/566,279 patent/US20150231235A1/en not_active Abandoned
2016
- 2016-06-03 JP JP2016111656A patent/JP6607825B2/ja active Active
- 2016-10-06 IL IL248204A patent/IL248204A0/en unknown
2018
- 2018-08-24 JP JP2018157054A patent/JP6907165B2/ja active Active
2019
- 2019-07-09 CY CY20191100718T patent/CY1121813T1/el unknown
- 2019-09-12 US US16/569,162 patent/US20200114000A1/en not_active Abandoned
- 2019-10-02 LU LU00128C patent/LUC00128I2/fr unknown
- 2019-10-02 LU LU00129C patent/LUC00129I2/fr unknown
- 2019-10-02 LU LU00130C patent/LUC00130I2/fr unknown
- 2019-10-04 LT LTPA2019516 patent/LTPA2019516I1/lt unknown
- 2019-10-04 LT LTPA2019514 patent/LTPA2019514I1/lt unknown
- 2019-10-04 LT LTPA2019515 patent/LTPA2019515I1/lt unknown
- 2019-10-09 FR FR19C1056C patent/FR19C1056I1/fr active Active
- 2019-10-09 FR FR19C1057C patent/FR19C1057I1/fr active Active
- 2019-10-09 FR FR19C1055C patent/FR19C1055I1/fr active Active
- 2019-10-10 HU HUS1900043 patent/HUS1900043I1/hu unknown
- 2019-10-10 HU HUS1900044 patent/HUS1900044I1/hu unknown
- 2019-10-10 CY CY2019035C patent/CY2019035I2/el unknown
- 2019-10-10 CY CY2019037C patent/CY2019037I2/el unknown
- 2019-10-10 HU HUS1900045 patent/HUS1900045I1/hu unknown
- 2019-10-10 CY CY2019036C patent/CY2019036I2/el unknown
2020
- 2020-07-03 CY CY2020016C patent/CY2020016I2/el unknown
- 2020-07-10 LT LTPA2020520C patent/LTPA2020520I1/lt unknown
- 2020-07-16 FR FR20C1034C patent/FR20C1034I1/fr active Active
2021
- 2021-05-12 JP JP2021080739A patent/JP2021119198A/ja active Pending
- 2021-12-17 HU HUS2100056C patent/HUS2100056I1/hu unknown
- 2021-12-17 HU HUS2100057C patent/HUS2100057I1/hu unknown
- 2021-12-20 LT LTPA2021014C patent/LTPA2021014I1/lt unknown
- 2021-12-20 CY CY2021038C patent/CY2021038I2/el unknown
- 2021-12-20 CY CY2021037C patent/CY2021037I2/el unknown
- 2021-12-20 FR FR21C1062C patent/FR21C1062I1/fr active Active
- 2021-12-20 FR FR21C1063C patent/FR21C1063I1/fr active Active
- 2021-12-20 LT LTPA2021015C patent/LTPA2021015I1/lt unknown
2023
- 2023-06-29 JP JP2023107054A patent/JP2023120436A/ja active Pending
- 2023-10-17 US US18/488,634 patent/US20240165226A1/en not_active Abandoned
2025
- 2025-04-16 FR FR25C1015C patent/FR25C1015I1/fr active Active
- 2025-04-17 FI FIC20250018C patent/FIC20250018I1/fi unknown
- 2025-04-17 LT LTPA2025516C patent/LTPA2025516I1/lt unknown
- 2025-04-17 HU HUS2500018C patent/HUS2500018I1/hu unknown
- 2025-07-11 JP JP2025116995A patent/JP2025143484A/ja active Pending

Also Published As

Publication number	Publication date
JP6907165B2 (ja)	2021-07-21
HUE044136T2 (hu)	2019-09-30
AU2007302448B2 (en)	2013-12-19
HUS2100057I1 (hu)	2022-01-28
WO2008037257A3 (fr)	2008-06-05
HUS1900043I1 (hu)	2019-11-28
FR21C1063I1 (fr)	2022-02-18
HUS1900045I1 (hu)	2019-11-28
US20240165226A1 (en)	2024-05-23
ES2732278T3 (es)	2019-11-21
CA2664740A1 (fr)	2008-04-03
AU2013203186C1 (en)	2019-02-14
LTPA2019516I1 (lt)	2019-10-25
JP2021119198A (ja)	2021-08-12
FR19C1057I1 (fr)	2019-11-15
US20150231235A1 (en)	2015-08-20
CY2019037I1 (el)	2020-05-29
LTPA2019514I1 (lt)	2019-10-25
FIC20250018I1 (fi)	2025-04-17
CY2021038I1 (el)	2022-03-24
FR19C1055I1 (fr)	2019-11-15
IL248204A0 (en)	2016-11-30
HUS1900044I1 (hu)	2019-11-28
TR201910145T4 (tr)	2019-08-21
AU2013203186B2 (en)	2016-06-16
LUC00128I2 (fr)	2024-05-22
FR19C1056I1 (fr)	2019-11-15
LTPA2021014I1 (fr)	2022-01-10
ME03503B (fr)	2020-04-20
CY2019036I1 (el)	2020-05-29
LTPA2021015I1 (fr)	2022-01-25
CY1121813T1 (el)	2020-05-29
LT2081595T (lt)	2019-07-10
DK2081595T3 (da)	2019-07-15
CY2019035I1 (el)	2020-05-29
EA034877B1 (ru)	2020-04-01
PT2081595T (pt)	2019-07-16
HUS2500018I1 (hu)	2025-05-28
CY2019036I2 (el)	2020-05-29
IL197727A (en)	2017-01-31
EA200970317A1 (ru)	2009-10-30
EP3569245A1 (fr)	2019-11-20
US20100092489A1 (en)	2010-04-15
FR25C1015I1 (fr)	2025-06-20
JP2025143484A (ja)	2025-10-01
CY2021037I1 (el)	2022-03-24
FR21C1062I1 (fr)	2022-02-18
JP2019001804A (ja)	2019-01-10
US9040050B2 (en)	2015-05-26
NZ576122A (en)	2012-09-28
CY2019037I2 (el)	2020-05-29
IL197727A0 (en)	2011-08-01
JP2023120436A (ja)	2023-08-29
HRP20191115T1 (hr)	2019-09-20
CY2019035I2 (el)	2020-05-29
AU2007302448A1 (en)	2008-04-03
EP3753576A1 (fr)	2020-12-23
JP2014141492A (ja)	2014-08-07
JP2010504363A (ja)	2010-02-12
RS59005B1 (sr)	2019-08-30
LTPA2019515I1 (lt)	2019-10-25
JP2016188228A (ja)	2016-11-04
AU2007302448C1 (en)	2019-02-14
EP2081595A2 (fr)	2009-07-29
LTPA2020520I1 (lt)	2020-07-27
JP6607825B2 (ja)	2019-11-20
WO2008037257A2 (fr)	2008-04-03
CY2020016I1 (el)	2020-11-25
HUS2100056I1 (hu)	2022-01-28
CY2021037I2 (el)	2022-03-24
LTPA2025516I1 (fr)	2025-05-12
PL2081595T3 (pl)	2019-11-29
US20200114000A1 (en)	2020-04-16
CY2020016I2 (el)	2020-11-25
AU2013203186A1 (en)	2013-05-02
CY2021038I2 (el)	2023-11-15
FR20C1034I1 (fr)	2020-10-02
SI2081595T1 (sl)	2019-10-30
LUC00130I2 (fr)	2024-05-22
CA2664740C (fr)	2021-11-16
EP2081595B1 (fr)	2019-04-10
JP5476122B2 (ja)	2014-04-23

Publication	Publication Date	Title
LTPA2025516I1 (fr)	2025-05-12
BE2015C016I2 (fr)	2025-12-10
BRPI0720064A2 (fr)	2017-08-15
BRMU8603216U8 (fr)	2012-10-16
BRPI0715824A8 (fr)	2008-02-28
BRPI0713487A2 (fr)	2012-11-13
BR122016023444A2 (fr)	2008-01-15
BRPI0708307B8 (fr)	2021-05-25
CH2121272H1 (fr)	2020-12-15
BY9789C1 (fr)	2007-10-30
CN300725931S (zh)	2008-01-02	童装(3815)
CN300725924S (zh)	2008-01-02	童装(3789)
CN300726122S (zh)	2008-01-02	牙刷板(p-400)
CN300725943S (zh)	2008-01-02	童装(3876)
CN300725942S (zh)	2008-01-02	童装(3874)
CN300725941S (zh)	2008-01-02	童装(3872)
CN300725940S (zh)	2008-01-02	童装(3870)
CN300725912S (zh)	2008-01-02	童装(3706)
CN300725913S (zh)	2008-01-02	童装(3712)
CN300725914S (zh)	2008-01-02	童装(3714)
CN300725915S (zh)	2008-01-02	童装(3728)
CN300725916S (zh)	2008-01-02	童装(3732)
CN300725917S (zh)	2008-01-02	童装(3734)
CN300725918S (zh)	2008-01-02	童装(3748)
CN300725919S (zh)	2008-01-02	童装(3752)